<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T01:48:02Z</responseDate>
  <request identifier="oai:figshare.com:article/33717424" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33717424</identifier>
        <datestamp>2026-09-14T04:25:22Z</datestamp>
        <setSpec>category_388</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Supplementary file 1_Modelling image quality over extended [18F]FDG uptake times for low-dose positron emission mammography.docx</dc:title>
          <dc:creator>Elliott De Benetti (24867331)</dc:creator>
          <dc:creator>Tobias Preckel (24867334)</dc:creator>
          <dc:creator>Apichart Linhananta (2177932)</dc:creator>
          <dc:creator>Brandon Baldassi (24867337)</dc:creator>
          <dc:creator>Borys Komarov (24867340)</dc:creator>
          <dc:creator>Harutyun Poladyan (24867343)</dc:creator>
          <dc:creator>Vivianne Freitas (14299747)</dc:creator>
          <dc:creator>Alla Reznik (20896790)</dc:creator>
          <dc:creator>Oleksandr Bubon (24867346)</dc:creator>
          <dc:subject>Oncology and Carcinogenesis not elsewhere classified</dc:subject>
          <dc:subject>[18F]FDG PEM</dc:subject>
          <dc:subject>breast cancer</dc:subject>
          <dc:subject>breast imaging</dc:subject>
          <dc:subject>delayed imaging</dc:subject>
          <dc:subject>image quality</dc:subject>
          <dc:subject>kinetic modelling</dc:subject>
          <dc:subject>positron emission mammography</dc:subject>
          <dc:description>Introduction&lt;p&gt;This study investigated the effect of [&lt;sup&gt;18&lt;/sup&gt;F]fluorodeoxyglucose ([&lt;sup&gt;18&lt;/sup&gt;F]FDG) uptake time on image quality in low-dose positron emission mammography (PEM) using kinetic modelling.&lt;/p&gt;Methods&lt;p&gt;Fifteen malignant lesions from thirteen women newly diagnosed with breast cancer were imaged using low-dose [&lt;sup&gt;18&lt;/sup&gt;F]FDG PEM. Tumour and normal breast tissue time-activity curves (TACs) were generated using a population-based arterial input function (AIF) and a two-tissue compartmental model. Modelling was performed at [&lt;sup&gt;18&lt;/sup&gt;F]FDG doses of 1, 2, 5, and 10 mCi (37, 74, 185, and 370 MBq), and image quality was assessed using contrast-to-noise ratio (CNR) over a 6-hour uptake period.&lt;/p&gt;Results&lt;p&gt;Extending uptake times beyond the 1-hour clinical standard significantly improved CNR across all doses, with comparable proportional gains. Relative to 1 hour post-injection, CNR increased by approximately 30% at 1.5 hours, 53% at 2 hours, and 77% at 3 hours, although uncertainty widened at 3 hours and beyond, particularly at the lowest dose (1 mCi). Relatively small variations in uptake time were also found to produce substantial changes in the standardized uptake value (SUV).&lt;/p&gt;Discussion&lt;p&gt;These findings demonstrate that extending uptake times by even 30 minutes beyond the 1-hour clinical standard may significantly enhance image CNR for low-dose [&lt;sup&gt;18&lt;/sup&gt;F]FDG PEM. The sensitivity of SUV to small variations in uptake time supports the need to closely match uptake time between baseline and follow-up scans in treatment response assessment. Overall, these modelling results encourage further clinical research into optimizing uptake time protocols, which may help support the broader adoption of low-dose PEM in future work.&lt;/p&gt;Clinical Trials Registration&lt;p&gt;https://clinicaltrials.gov/study/NCT03520218, identifier NCT03520218.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-14T04:25:22Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fonc.2026.1880803.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Supplementary_file_1_Modelling_image_quality_over_extended_18F_FDG_uptake_times_for_low-dose_positron_emission_mammography_docx/33717424</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
